Home › Free Stock Grades › FHTX
Foghorn Therapeutics Inc. (FHTX) Stock Grade
FHTX · Healthcare
A+
Market Cap
$340.1M
P/E Ratio
—
Revenue Growth (YoY)
+36.8%
Net Margin
-240.3%
Return on Equity
68.5%
Dividend Yield
None
About Foghorn Therapeutics Inc.'s fundamentals
Foghorn Therapeutics is a biotechnology company with a market capitalization of $340.1 million that reported strong revenue growth of 36.8% year-over-year, indicating expanding commercial traction. However, the company is currently unprofitable, posting a net margin of -240.3% and reporting a net loss in its latest annual statement, which reflects the typical cash-burn profile of early-stage biotech firms. The company does not pay a dividend and has no trailing P/E ratio due to its loss position.